Team:RAMNOTIREN CALGARY

From 2014hs.igem.org

(Difference between revisions)
 
(112 intermediate revisions not shown)
Line 5: Line 5:
<style>
<style>
h1{
h1{
-
font-size: 2.5em;
+
font-size: 1em;
 +
                        display: none;
}
}
-
               
+
 
-
                 h2{
+
                 #firstheading {
-
                      font-size: 25.5px;
+
                        display: none;
                 }
                 }
-
 
h3{
h3{
Line 19: Line 19:
p {
p {
text-indent:50px;
text-indent:50px;
-
}
+
}  
-
#box1{
+
#box1 {
-
width: 968px;
+
width: 990px;
margin-top: 8px;
margin-top: 8px;
background: #E6E6E6; /*threedface*/
background: #E6E6E6; /*threedface*/
Line 28: Line 28:
padding-bottom: 20px;
padding-bottom: 20px;
margin-bottom: 13px;
margin-bottom: 13px;
 +
position: relative;
 +
left: -60px;
 +
                     
}
}
-
#box1 h3{
+
#box1 h3 {
-
padding: 30px 0px 0px 0px;
+
padding: 20px 0px 0px 10px;
-
text-align: center;
+
font-family: arial, verdana, "lucida sans";
font-family: arial, verdana, "lucida sans";
 +
                        text-align: center;
 +
                       
}
}
-
#box1 p{
+
#box1 p {
-
padding: 0px 60px 0px 350px;
+
padding: 5px 30px 5px 30px;
font-family: arial, verdana, "lucida sans";
font-family: arial, verdana, "lucida sans";
font-size: 15px;
font-size: 15px;
Line 106: Line 110:
border: none;  
border: none;  
width: 300px;
width: 300px;
-
}
 
-
 
-
#footer-box {
 
-
background-color: #216085;
 
-
border: none;
 
-
width: 850px;
 
-
height: 30px;
 
-
margin: -10px auto 0 auto;
 
-
padding: 20px 0;
 
}
}
.visualClear {  
.visualClear {  
display: none;  
display: none;  
-
}
 
-
 
-
#footer {
 
-
border: none;
 
-
width: 850px;
 
-
margin: 0 auto;
 
-
padding: 0;
 
}
}
Line 132: Line 120:
}
}
-
#f-list a {
 
-
color: #333;
 
-
font-size: 10px;
 
-
}
 
-
 
-
#f-list a:hover {
 
-
color: #666;
 
-
}
 
-
 
-
.printfooter {
 
-
display: none;
 
-
}
 
-
 
-
#footer ul {
 
-
margin: 0;
 
-
padding: 0;
 
-
}
 
-
 
-
#footer ul li {
 
-
margin-top: 0;
 
-
margin-bottom: 0;
 
-
margin-left: 10px;
 
-
margin-right: 10px;
 
-
padding: 0;
 
-
}
 
#search-controls {  
#search-controls {  
Line 162: Line 125:
}
}
-
h3#siteSub {  
+
#siteSub {  
display: none;
display: none;
}
}
Line 179: Line 142:
clear: both;
clear: both;
}
}
 +
.progress{
.progress{
Line 184: Line 148:
}
}
-
.plus {
+
#vidbutt{
-
        display: inline-block;
+
position: relative;
-
        -webkit-transition: 1s ease-in-out;
+
top:0px;
-
        -moz-transition: 1s ease-in-out;
+
left:-60px;
-
        -o-transition: 1s ease-in-out;
+
background-color: #e6e6e6;
-
    }
+
padding: 0px 15px 0px 15px;
-
     
+
border-radius: 5px;
-
    .menu:hover .plus {
+
}
-
        -webkit-transform: rotate(1000deg);
+
 
-
        -moz-transform: rotate(1000deg);
+
#notebutt{
-
        -o-transform: rotate(1000deg);
+
position: relative;
-
    }
+
top: -300px;
 +
left: 286px;
 +
background-color: #e6e6e6;
 +
padding: 0px 15px 20px 15px;
 +
border-radius: 5px;
 +
}
 +
 
 +
 
 +
 
 +
        #tweets{
 +
      position: relative;
 +
top:-834px;
 +
left:642px;
 +
      width: 280px;   
 +
}
 +
      #countdown{
 +
      position: relative;
 +
top: -815px;
 +
left:642px;
 +
}
 +
 
 +
    #sponsorsbox{
 +
clear: both;
 +
position: relative;
 +
                top: -600px;
 +
                left: -70px;
 +
width: 1005px;
 +
margin: 4px 0px;
 +
background: #EEEEEE;
 +
                border-radius: 3px;
 +
}
 +
#sponsorsbox h4{
 +
padding: 20px 20px 0px 20px
 +
}
 +
#sponsorsbox p{
 +
padding: 0px 20px;
 +
}
 +
#sponsorsbox table{
 +
width: 950px;
 +
margin-left: auto;
 +
margin-right: auto;
 +
background: #EEEEEE;
 +
}
 +
#sponsorsbox td{
 +
padding: 15px 0px;
 +
width: 300px;
 +
}
 +
#sponsorsbox img{
 +
display: block;
 +
margin-right: auto;
 +
margin-left: auto;
 +
}
 +
 +
    #exp1{
 +
      position: relative;
 +
top:-310px;
 +
left:-58px;
 +
      background-color: #e6e6e6;
 +
      padding: 10px 10px 10px 10px;
 +
width: 308px;
 +
    }
 +
 +
    #exp2{
 +
      position: relative;
 +
top:-405px;
 +
left: 288px;
 +
      background-color: #e6e6e6;
 +
            padding: 10px 10px 10px 10px;
 +
width: 308px;
 +
    }
</style>
</style>
Line 245: Line 278:
         setInterval( "slider()", 5000 );
         setInterval( "slider()", 5000 );
     });
     });
 +
 +
    /*js for twitter feed*/
 +
    !function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");
   
   
</script>
</script>
Line 261: Line 297:
     <li class='selected'><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY">Page</a></li>
     <li class='selected'><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY">Page</a></li>
<li class='new'><a href="https://2014hs.igem.org/wiki/index.php?title=Talk:Team:RAMNOTIREN_CALGARY&action=edit&redlink=1">Discussion</a></li>
<li class='new'><a href="https://2014hs.igem.org/wiki/index.php?title=Talk:Team:RAMNOTIREN_CALGARY&action=edit&redlink=1">Discussion</a></li>
-
    <li><a href="2014hs.igem.org/wiki/index.php?title=Team:RAMNOTIREN_CALGARY/Notebook&action=edit">View Source</a></li>
+
    <li><a href="https://2014hs.igem.org/wiki/index.php?title=Team:RAMNOTIREN_CALGARY&action=edit">View Source</a></li>
    <li><a href="https://2014hs.igem.org/wiki/index.php?title=Team:RAMNOTIREN_CALGARY&action=history">History</a></li>
    <li><a href="https://2014hs.igem.org/wiki/index.php?title=Team:RAMNOTIREN_CALGARY&action=history">History</a></li>
    <li><a href="https://igem.org/Login">Log in</a></li>
    <li><a href="https://igem.org/Login">Log in</a></li>
Line 284: Line 320:
<ul id="menu">
<ul id="menu">
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/‎" id="homelink">Home</a></li>
+
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY‎" id="homelink">Home</a></li>
-
<li><a href="2014hs.igem.org/Team:RAMNOTIREN_CALGARY‎/Team" id="teamlink">Team</a>
+
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members" id="teamlink">Team</a>
<ul>
<ul>
-
<li><a href="2014hs.igem.org/Team:RAMNOTIREN_CALGARY‎/Team">Members</a></li>
+
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members">Members</a></li>
-
<li><a href="https://igem.org/Team.cgi">Official Profile</a></li>
+
<li><a href="https://igem.org/Team.cgi?id=1295" target="_blank">Official Profile</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/AboutCMHS">About CMHS</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/AboutCMHS">About CMHS</a></li>
</ul>
</ul>
</li>
</li>
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project" id="projectlink">Project </a>
+
                                  <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content" id="projectlink">Content</a>
<ul>
<ul>
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content">Content</a></li>
+
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content">Overview</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/HumanPractices">Human Practices</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/HumanPractices">Human Practices</a></li>
 +
                                                <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Safety">Safety</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/References">References</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/References">References</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Attributions">Attributions</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Attributions">Attributions</a></li>
Line 305: Line 342:
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Parts" id="partslink">Parts</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Parts" id="partslink">Parts</a></li>
-
<li><a class="drop" href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Notebook" id="notebooklink">Notebook</a>
+
<li><a class="drop" href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Notebook" id="notebooklink">Notebook</a></li>
-
<ul>
+
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Notebook">Journal</a></li>
+
-
</ul>
+
-
</li>
+
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Sponsors" id="sponsorslink">Sponsors</a></li>
+
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Protocols" id="protocollink">Protocols</a></li>
<li><a href="https://2014hs.igem.org" target="_blank">iGEM</a></li>
<li><a href="https://2014hs.igem.org" target="_blank">iGEM</a></li>
Line 318: Line 351:
</header>
</header>
-
<div id="box1" align="justify">
+
<div id="box1"> <!--align="justify"-->
-
<a href="#"></a>
+
<h3>Choking Cancer</h3>
<h3>Choking Cancer</h3>
-
 
<p>Every year approximately eight million people die of cancer, and an additional fourteen million are diagnosed with the disease. The World Heath Organization predicts that without immediate action these numbers will increase by eighty percent by the year 2030.</p><p>Cancer needs an abundant source of oxygenated blood to grow. To achieve this cancer cells release angiogenic factors that promote vascular growth. Without these factors, cancer is unable to survive.  Consequently, current treatments focus on targeting/inhibiting the angiogenic factors released by cancer cells. Targeted therapy has also been a successful treatment option.</p><p>Our project aims to combine these two therapeutic approaches to create a synthetic biological machine that seeks out cancer cells and inhibits angiogenesis. We plan to design a bacterium that in the presence of cancer cells secretes an anti-angiogenic factor.  This will inhibit the growth of the capillary system that is crucial for cancer cell survival.</p>
<p>Every year approximately eight million people die of cancer, and an additional fourteen million are diagnosed with the disease. The World Heath Organization predicts that without immediate action these numbers will increase by eighty percent by the year 2030.</p><p>Cancer needs an abundant source of oxygenated blood to grow. To achieve this cancer cells release angiogenic factors that promote vascular growth. Without these factors, cancer is unable to survive.  Consequently, current treatments focus on targeting/inhibiting the angiogenic factors released by cancer cells. Targeted therapy has also been a successful treatment option.</p><p>Our project aims to combine these two therapeutic approaches to create a synthetic biological machine that seeks out cancer cells and inhibits angiogenesis. We plan to design a bacterium that in the presence of cancer cells secretes an anti-angiogenic factor.  This will inhibit the growth of the capillary system that is crucial for cancer cell survival.</p>
 +
</div>
</div>
-
<!--
+
<div id="button1">
-
<div id="sponsorsbox">
+
  <a href="http://www.youtube.com/watch?v=C_5Z31mUmtc"><img id="vidbutt" src="https://static.igem.org/mediawiki/2014hs/6/67/VideoButton.png" width="300px" height="300px"></a>
-
<h2>Thanks to Our Sponsors!</h2>
+
</div>
-
<table>
+
-
<tr>
+
-
<td><a href="http://www.ucalgary.ca/bhsc/node/16" target="_blank"><img style="width: 284px;" src="https://static.igem.org/mediawiki/2012/d/d6/UCalgary2012_Logo_O%27Brien_Centre.png"></img></a></td> <-EXAMPLE
+
-
</tr>
+
-
</table>
+
-
-->
+
-
+
-
<!--Scroll back to top-->
+
-
<!--this is for a  styled back to top button
+
<div id="button2">
-
<div class="back-to-top" id="back-top">
+
  <a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Notebook"><img id="notebutt" src="https://static.igem.org/mediawiki/2014hs/9/95/Notebook.png" width="300px" height="300px"></a>
-
<a href="javascript:void(0)" class="back-to-top">Top</a>
+
-
</div>
+
-
+
-
<script type="text/javascript">
+
-
$(function () {
+
-
    $("#back-top").hide();
+
-
    $(window).scroll(function () {
+
-
        if ($(this).scrollTop() > 150) {
+
-
            $('#back-top').fadeIn();
+
-
        }
+
-
        else {
+
<div id="exp1">
-
            $('#back-top').fadeOut();
+
<p>Click here to see the introductory video we used to familiarize ouselves with what we would be researching. </p>
-
        }
+
</div>
-
    });
+
-
});
+
-
jQuery('.back-to-top').click(function () {
+
-
    jQuery('html, body').animate({
+
-
        scrollTop: 0
+
-
    }, 'slow');
+
-
});
+
-
</script>
+
-
pray to God that this code works. major bonus points-->
+
 +
<div id="exp2">
 +
<p>Here is a record of our. We also want to thank everybody who helped us along the way!</p>
 +
</div>
-
<body>
+
 
 +
  <div id="tweets">
 +
    <a class="twitter-timeline"  href="https://twitter.com/CentraliGEM"  data-widget-id="475046068170674176">Tweets by @CentraliGEM</a>
 +
    <script>!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");</script>
 +
</div>
 +
 
 +
<div id="countdown">
 +
<iframe src="http://free.timeanddate.com/countdown/i478w11x/n43/cf111/cm0/cu4/ct3/cs1/ca2/co1/cr2/ss0/cac000/cpc000/pc9542aa/tc9542aa/fs90/szw256/szh108/tatCountdown%20to%20iGEM%20Jamboree/tac000/tptTime%20since%20Event%20started%20in/tpc000/iso2014-06-26T00:00:00/bo2" frameborder="0" width="258" height="110"></iframe>
 +
 
 +
</div>
 +
 
 +
 
 +
<div id="sponsorsbox">
 +
  <h4>
 +
    Our Sponsors
 +
  </h4>
 +
  <table>
 +
    <tr>
 +
      <td><a href="http://www.albertatechfutures.ca" target="_blank"><img style="width: 284px;" src="https://static.igem.org/mediawiki/2014hs/7/7a/AlbertaInno.png"/></a></td>
 +
      <td><a href="http://www.albertatechfutures.ca/AcademicProgramsiCORE/geekStarter.aspx" target="_blank"><img style="width: 284px;" src="https://static.igem.org/mediawiki/2014hs/0/0d/GeekStarter.png"/></a></td>
 +
      <td><a href="http://schools.cbe.ab.ca/b823/default.html" target="_blank"><img style="width= 284px;" src="https://static.igem.org/mediawiki/2014hs/6/6a/Ram.png"/></a></td>
 +
    </tr>
 +
  </table>
 +
</div>
</body>
</body>
</html>
</html>

Latest revision as of 04:02, 21 June 2014

Choking Cancer

Every year approximately eight million people die of cancer, and an additional fourteen million are diagnosed with the disease. The World Heath Organization predicts that without immediate action these numbers will increase by eighty percent by the year 2030.

Cancer needs an abundant source of oxygenated blood to grow. To achieve this cancer cells release angiogenic factors that promote vascular growth. Without these factors, cancer is unable to survive. Consequently, current treatments focus on targeting/inhibiting the angiogenic factors released by cancer cells. Targeted therapy has also been a successful treatment option.

Our project aims to combine these two therapeutic approaches to create a synthetic biological machine that seeks out cancer cells and inhibits angiogenesis. We plan to design a bacterium that in the presence of cancer cells secretes an anti-angiogenic factor. This will inhibit the growth of the capillary system that is crucial for cancer cell survival.

Click here to see the introductory video we used to familiarize ouselves with what we would be researching.

Here is a record of our. We also want to thank everybody who helped us along the way!

Our Sponsors

Retrieved from "http://2014hs.igem.org/Team:RAMNOTIREN_CALGARY"